In this issue of the Journal, Goldberger et al. (7) examine the association between doses of prescribed beta-blockers and survival after MI using data from a prospective multicenter registry, the OBTAIN (Outcomes of Beta-Blocker Therapy After Myocardial INfarction) study. The OBTAIN study was initiated in 2007 as a companion registry to the PACE-MI (PACEmaker and Beta-blocker Therapy Post-Myocardial Infarction) trial, an National Heart, Lung, and Blood Institute-sponsored randomized controlled trial designed to assess whether pacemaker facilitated betablocker therapy improves survival after MI in patients with a bradycardia contraindication to beta-blockers (8). Data from the PACE-MI trial revealed near universal beta-blocker utilization, but at doses that were mostly #25% of target doses used in clinical trials (9).
Clinical practice guidelines (4-6) provide a Class I recommendation for the use of beta-blockers in patients without contraindications during and after presentation with acute coronary syndromes, with a preference for the long-term use of extended release metoprolol, carvedilol, or bisoprolol in those patients with heart failure or LV systolic dysfunction (5, 6) . The evidence base supporting the recommendation that beta-blockers be continued for 3 years in acute coronary syndromes patients with normal LV function is not robust. It has long been recognized that the majority of post-MI survivors are prescribed doses of beta-blockers well below those used in randomized trials, despite acknowledgment that beta-blocker dose-dependent heart rate lowering may play a role in extending survival.
In this issue of the Journal, Goldberger et al. (7) examine the association between doses of prescribed beta-blockers and survival after MI using data from a prospective multicenter registry, the OBTAIN (Outcomes of Beta-Blocker Therapy After Myocardial INfarction) study. The OBTAIN study was initiated in 2007 as a companion registry to the PACE-MI (PACEmaker and Beta-blocker Therapy Post-Myocardial Infarction) trial, an National Heart, Lung, and Blood Institute-sponsored randomized controlled trial designed to assess whether pacemaker facilitated betablocker therapy improves survival after MI in patients with a bradycardia contraindication to beta-blockers (8) . Data from the PACE-MI trial revealed near universal beta-blocker utilization, but at doses that were mostly #25% of target doses used in clinical trials (9) .
In the OBTAIN study, 6,682 consecutive patients discharged alive after MI were assessed over a median follow up of 2.1 years. The 91.5% of patients discharged on a beta-blocker were grouped into 1 of 4 categories defined by the percent of target dose prescribed (0% to 12.5%, >12.5% to 25%, >25% to 50%, >50%). The most frequently prescribed dose was >12.5% to 25% of target dose; fewer than 15% of patients were discharged on Massachusetts. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. As with many observational studies, the study's results must be interpreted with caution. In the OBTAIN study, beta-blocker use and dosing at time of discharge were not pre-specified. Prescribing decisions were left to the treating physician, who presumably exercised judgment regarding the safety and efficacy of a beta-blocker rather than simply failed to provide it absent a clear contraindication. As a group, patients discharged without a beta-blocker were older and more likely to have a history of heart failure or chronic obstructive pulmonary disease, lower admission blood pressure, greater incidence of non-ST-segment elevation MI relative to ST-segment elevation MI, and a higher mortality rate compared with those patients discharged on any beta-blocker.
Some of the patients who were considered not to be candidates for beta-blockers may constitute a group for which their use is particularly beneficial, especially those with heart failure or unstable rhythms.
Such patients usually require more cautious drug initiation and dose titration, aspects of care that are not accommodated by rapid discharge planning.
Despite careful efforts at multivariable adjustment and propensity score matching, additional differences unaccounted for among the 4 pre-specified patient subgroups may have influenced outcomes. To what extent did differences in clinical characteristics ( We can also speculate regarding the degree to which the effectiveness of beta-blockers in MI survi- clinicians are left today with the sobering statistics that 50% or fewer of patients prescribed any dose of beta-blockers following acute MI at hospital discharge are still using them 1 or 2 years later (17, 18) . We look forward to a personalized approach to cardiovascular care that moves toward patient-specific drug target effects while reducing major morbidity and mortality, but recognize that this will require a better partnership between us and our patients. 
